Teralys Capital

Turnstone Biologics is a privately-held clinical-stage biotech company. Turnstone Biologics’ mission is to deliver breakthrough cancer immunotherapies by advancing two leading and complementary platforms targeting tumor immunity, to improve survival for people with cancer.

Verafin provides a cloud-based cross-institutional software platform for Fraud Detection and Management, BSA/AML Compliance and Management, High-Risk Customer Management, and Secure 314(b) Information Sharing. More than 2600 banks and credit unions use Verafin to effectively fight financial crime and comply with regulations. Leveraging its big data intelligence, visual storytelling, and collaborative investigation capabilities, Verafin significantly reduces false positive alerts, delivers context-rich insights, and streamlines the daunting BSA/AML compliance processes that financial institutions face today. Verafin is the exclusive provider for Texas Bankers Association, Western Bankers Association, Florida Bankers Association, Illinois Bankers Association, Massachusetts Bankers Association, and CUNA Strategic Services, with industry endorsements in 47 U.S. states.

Busbud is a mobile app and platform that connects passengers to bus operators. It enables its users to search, compare, and book city-to-city bus tickets for any location and from any location. It is a comprehensive source of city-to-city bus schedules and tickets around the world, gathering schedules for over 10463 cities in 89 countries, in 10 languages, and 15 currencies. The app offers a search tool allowing travelers to discover and plan their next bus trip. Busbud was founded by Michael Gradek, LP Maurice, and Frederic Thouin in October 2011. It is headquartered in Montreal City in Québec, Canada.

Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases. Zymeworks' approach combines proprietary molecular modeling and simulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization. It was founded in 2004 and headquartered in Vancouver, British Columbia.